Low-dose version of Prempro approved

Share this article:
The FDA approved a low-dose version of Wyeth Pharmaceuticals' hormone replacement therapy Prempro (conjugated estrogens and medroxyprogesterone). The low-dose Prempro has 28 percent less estrogen and 40 percent less progestin than full-dose Prempro, Wyeth reported. It contains 0.45 mg of conjugated estrogens and 1.5 mg of medroxyprogesterone. This version is indicated for use in the treatment of moderate to severe vasomotor symptoms associated with menopause, such as hot flashes and night sweats. It is also approved for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy, such as vaginal dryness. Wyeth said data supporting the efficacy and tolerability of low-dose Prempro is based on the Women's HOPE study, which included 2,805 postmenopausal women.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.